Novo Holdings leads Clasp Therapeutics’ $150m fundraiser Novo Holdings co-led Clasp Therapeutics’ $150 million fundraiser to develop precision immune-oncology using next-generation T-cell engagers. Clasp is leveraging advances made by its scientific founders at Johns Hopkins University, including leading cancer geneticist and HHMI investigator Bert Vogelstein, M.D., and immuno-oncology pioneer Drew Pardoll, M.D., Ph.D., who have […]
AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]
Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
Neuraxpharm launches RMS drug in Europe, calls for awareness of rare disease In another exciting week for Optimum’s clients, Neuraxpharm kicked off proceedings with the first launch of Briumvi (ublituximab) in Europe, for treatment of relapsing multiple sclerosis. Germany is the first country to see the launch of the drug following Neuraxpharm’s agreement with TG […]
It was an exciting week for Optimum’s clients with a slew of scientific data announced ahead of the ESMO Targeted Anticancer Therapies Conference 2024 – a high-profile cancer conference on the 26 February. STORM to present findings of First-in-Class METTL1 tRNA Methyltransferase Inhibitors STORM Therapeutics Ltd, the clinical stage biotechnology company discovering and developing novel […]
